Find a company
Huma’s mission is to help people live longer, fuller lives, and one of the ways we do this is through our remote patient monitoring platform which advances connected care for patients and accelerates research and therapies. In healthcare settings, Huma's technology has demonstrated reduced hospital admissions (by >30%), reduced length of stay (by ~40%) and enhancement to clinical capacity (almost doubled), whilst achieving >90% adherence. The technology has won a number of national and international awards including the Prix Galien International 2022 ‘best of the best digital health product’ award.
| Project | A digital first, population-level, early detection, engagement and self-management programme for people who are undiagnosed and/or high-risk of developing modifiable Cardiovascular Disease (CVD) |
|---|---|
| Description |
Huma’s remote patient monitoring (RPM) platform connects patients and clinical teams through smartphone-based technology. Huma’s primary care arm – iPlato – are experts in enhancing patient access and engagement through technology. For this project, Huma and iPlato’s technologies will proactively engage and support people who are identified by their GPs as being high-risk of undiagnosed CVD. |
| Funding | £ 493,877 |
| Competition | Competition 21 - Phase 3, Real-world Implementation: Respiratory Diseases and Cardiovascular Diseases |
| Competition Date | June 2022 |
| Categories | Cardiovascular |
| Health Innovation Network Partner | UCL Partners |
| Website | https://www.huma.com |